Clinical trial · Interventional
Selenium in the Prevention of Cancer
Prevention of Cancer by Intervention With Selenium - A Pilot Study in a Danish Population
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot study proceeding an intended international trial. Hypothesis: Daily intake of selenium supplementation in the form of selenium-enriched yeast tablets will reduce the risk of cancer in healthy individuals. Objective: The objective of this pilot study was to assess the viability of a full scale randomised trial. AMENDMENT TO STUDY OBJECTIVE: Mortality analysis during intervention and follow-up as specified in the sections concerning study design and outcome measures.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d
- interventionNames
- Dietary Supplement: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
- type
- EXPERIMENTAL
- label
- Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d
- interventionNames
- Dietary Supplement: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
- type
- EXPERIMENTAL
- label
- Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d
- interventionNames
- Dietary Supplement: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * WHO performance status 0 or 1 * No active liver- or kidney disease (Serum ALAT (alanine aminotransferase), alkalic phosphatase, bilirubin, creatinin or urea within 2 S.D of laboratory reference range) * No previous cancer diagnosis * No known HIV-infection * Participant must understand oral and written information * Participant must not use selenium supplementation of above 50 mcg/d * Participant must give written consent prior to inclusion
References
Publications (1)
- DERIVEDCold F, Winther KH, Pastor-Barriuso R, Rayman MP, Guallar E, Nybo M, Griffin BA, Stranges S, Cold S. Randomised controlled trial of the effect of long-term selenium supplementation on plasma cholesterol in an elderly Danish population. Br J Nutr. 2015 Dec 14;114(11):1807-18. doi: 10.1017/S0007114515003499. Epub 2015 Sep 30. PMID 26420334